Sermorelina

Precios por volumen

Precio por envase (10 viales). El descuento se aplica únicamente a este compuesto; no se admiten combinaciones.

Sermorelin — Endogenous GHRH Fragment and Somatotroph Secretagogue

Sermorelin is a synthetic 29-amino acid peptide corresponding to the N-terminal fragment of endogenous growth hormone-releasing hormone (GHRH), designated GHRH(1-29)NH₂. The compound was characterized during the 1970s and 1980s as researchers mapped the minimal active sequence of hypothalamic GHRH required for full biological activity at pituitary somatotrophs. It was subsequently approved by the FDA as Geref (sermorelin acetate) for diagnostic assessment of growth hormone secretory capacity and for treatment of idiopathic growth hormone deficiency in children — an approval that remained active until voluntary market withdrawal in 2008 for commercial rather than safety reasons. Sermorelin’s mechanism is fundamentally different from exogenous GH administration: it acts upstream at the pituitary, preserving the physiological pulsatile release pattern that characterizes normal somatotroph function. The 29-residue sequence retains full receptor activity compared to native 44-residue GHRH, and its relatively short plasma half-life (approximately 10–12 minutes) makes it a tractable tool compound for GH axis characterization in research settings.

Why Sermorelin’s Pituitary-Level Action Matters

Sermorelin acts on the GHRH receptor (GHRHR), a Gs-coupled GPCR expressed specifically on anterior pituitary somatotroph cells. GHRHR activation elevates intracellular cAMP via adenylyl cyclase, which drives both acute GH release and longer-term GH gene transcription. Because sermorelin stimulates endogenous GH secretion rather than bypassing it, the physiological feedback loop via somatostatin remains intact — a critical distinction for research models examining the full hypothalamic-pituitary-somatotroph axis. This preserved feedback architecture means IGF-1 elevation follows normal somatotroph kinetics rather than the supraphysiological curves produced by direct GH injection.

Aplicaciones de investigación

Sermorelin is used in studies examining:

• GH axis characterization and pituitary secretory reserve assessment
• GH deficiency models — pediatric and adult somatotroph insufficiency
• IGF-1 regulation downstream of GHRH stimulation
• Pulsatile vs. continuous GH secretion pattern comparison
• Somatotroph receptor pharmacology and GHRHR binding kinetics
• Age-related GH axis decline in rodent aging models
• Comparison with longer-acting GHRH analogues (CJC-1295, tesamorelin) in half-life and receptor occupancy studies

Especificaciones

Reconstitución

Sermorelin arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total en mg ÷ Volumen añadido (mL) = Concentración (mg/mL)

Ejemplo: vial de 5 mg + 1 ml de agua destilada = solución de 5 mg/ml

El péptido reconstituido debe conservarse a una temperatura de entre 2 y 8 °C y utilizarse en un plazo de 28 a 30 días.

Notas sobre el protocolo

Research frameworks for sermorelin are grounded in its former FDA-approved clinical use and published pediatric/adult GH deficiency literature. Diagnostic protocols used single-dose IV bolus administration; therapeutic research used lower-dose subcutaneous administration at bedtime to align with physiological nocturnal GH secretion patterns.

• Dose range (diagnostic literature): 1 mcg/kg IV bolus for GH stimulation testing
• Dose range (therapeutic literature): 0.2–0.3 mcg/kg SC, administered at bedtime in published clinical trials
• Frequency: Once daily in therapeutic research protocols
• Study duration: 3–12 months in published GH deficiency and GH axis studies

Pilas de investigación

Sermorelin is commonly paired in research settings with:

• CJC-1295 No DAC — CJC-1295 No DAC is a GHRH analogue with a slightly longer half-life than Sermorelin; researchers pair both to compare receptor occupancy kinetics and downstream GH pulse amplitude within the same model, isolating the effects of half-life on pituitary responsiveness.
• Ipamorelin — Ipamorelin stimulates GH secretion via the ghrelin receptor (GHS-R1a), a mechanism distinct from Sermorelin’s GHRH receptor engagement. The combination is studied to examine additive GH pulse effects arising from simultaneous GHRH axis and ghrelin axis activation.
• GHRP-2 — GHRP-2 is a potent GHS-R1a agonist with additional effects on cortisol and prolactin; pairing with Sermorelin is used in research to examine the hormonal sequelae of combined GHRH receptor and ghrelin receptor stimulation.

Garantía de pureza

Cada lote tiene una pureza ≥99 %. Si sometes tu compuesto a un análisis independiente y los resultados no coinciden, envíanos el certificado de análisis (COA) y te concederemos un vale de compra sin hacerte preguntas.